glimepiride
AssetAlso CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet, HOE490, Amaryl, Amaryl M
Sulfonylurea that stimulates insulin secretion by blocking ATP-sensitive potassium channels in pancreatic beta cells.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Insulin/IGF-1 signalling
- 3
- Indications
- 93
- Trials
- 2
- Developers
Indications
4No named disease
Approved, accessdata.fda.gov, 7 Oct 2026
Diabetes mellitus
Phase 3, Completed, NCT00642915, clinicaltrials.gov, 7 Oct 2026
Non insulin dependent diabetes mellitus
Phase 3, Completed, NCT00044447, clinicaltrials.gov, 7 Oct 2026
1 more
In the full profile
- Targets and what it contains3
- Owner and partners2
- Trials93
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 7 sources